2023
DOI: 10.1016/j.eururo.2023.02.007
|View full text |Cite
|
Sign up to set email alerts
|

Erratum to “European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel” [Eur. Urol. 79(4) (2021) 480–488]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(10 citation statements)
references
References 0 publications
0
10
0
Order By: Relevance
“…For patients under surveillance for NMIBC, the risk of tumor recurrence and progression depends on tumor characteristics [7,8]. As treatment recommendations are based on disease prognosis, the EAU defined the NMIBC risk classification based on the risk of progression of disease.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…For patients under surveillance for NMIBC, the risk of tumor recurrence and progression depends on tumor characteristics [7,8]. As treatment recommendations are based on disease prognosis, the EAU defined the NMIBC risk classification based on the risk of progression of disease.…”
Section: Discussionmentioning
confidence: 99%
“…As treatment recommendations are based on disease prognosis, the EAU defined the NMIBC risk classification based on the risk of progression of disease. The 5-year risk of tumor progression for low-risk intermediate-risk, high-risk, and very high-risk patients is 0.57, 3.6, 11, and 44%, respectively [7]. The risk of tumor recurrence within 1 year is 15, 24, 38, and 61% for low-risk, intermediate-risk, high-risk, and very high-risk patients [8].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…With a median follow-up of 38.8 months, only one patient experienced disease progression to MIBC, but the authors did not provide the patient's tumor stage before the AS period [37 && ]. Nevertheless, pT1 tumors have the highest risk of progression to MIBC [40,41]. For instance, the only progression to MIBC in the AS cohort reported by Hernandez et al occurred in patients with pT1G2 at inclusion [34].…”
Section: Pathological Tumor Stage and Gradementioning
confidence: 95%
“…a median time to recurrence of 5.7 years compared to 2.5 years for patients with tumors >10mm [40,41,52]. However, the high risk of recurrence does not contribute to an increase in mortality in TaLG [5,6].…”
Section: Tumor Size and Location Characteristicsmentioning
confidence: 95%